by will | Oct 31, 2025
BioPharma Human Immune Repertoire Antibody Library Human antibody repertoires offer vast therapeutic potential, yet most libraries derive from infected or immunized donors, limiting diversity and stability. Antibodies from naturally resilient individuals provide...
by will | Oct 31, 2025
BioPharma Synthetic Human Antibody Library for Broad Target Screening Monoclonal antibody therapeutics are among the most successful drug classes, yet traditional discovery methods rely on immunisation or donor-derived B-cell repertoires. These approaches can be slow,...
by will | Oct 29, 2025
BioPharma Monocyte reprogramming for Rheumatoid Arthritis Rheumatoid arthritis is an autoimmune disease that leads to the progressive destruction of joints. The disease is not curable and requires life-long treatment. Queen Mary researchers recently uncovered a novel...
by will | Oct 29, 2025
BioPharma Predicting sensitivity to disease-modifying antirheumatic drugs with pro-resolving mediators Rheumatoid arthritis is an autoimmune disease that leads to the progressive destruction of joints. The disease is not curable and requires life-long treatment. It is...
by will | Jul 29, 2025
BioPharma Predicting patient response to arthritis treatment using machine learning 1 in 100 people in Britain today live with rheumatoid arthritis (RA). Unlike osteoarthritis (OA), RA is caused not by wear and tear but by the body’s immune system attacking its own...
